Recent Updates
Recently added Catalysts
ABCL Positive Sentiment

AbCellera to Present at Upcoming Investor Conferences in November 2026

Key Takeaway: AbCellera (Nasdaq: ABCL) announced its participation in two investor conferences in November 2026. The Stifel Healthcare Conference is scheduled for November 11, followed by the Jefferies Global Healthcare Conference in London on November 16. Live audio webcasts of the presentations will be accessible on their Investor Relations website.

Market Sentiment Analysis

POSITIVE FACTORS

  • AbCellera will present at two major investor conferences.
  • The company focuses on developing first-in-class antibody-based medicines.
  • Live audio webcasts will be available for presentations.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+312%
120-day peak, hindsight
Typical move
4.8%
average across 5 past catalysts
Lead asset
ABCL635
Phase 1 · Vasomotor Symptoms Associated With Menopause

Full Press Release Details

VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) announced that the Company will present at the following investor conferences:
• Stifel Healthcare Conference, November 11, 2026
• Jefferies Global Healthcare Conference in London, November 16, 2026
A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website . A replay will be available through the same link following the presentation.
About AbCellera Biologics Inc.
AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines in the areas of endocrinology, women’s health, immunology, oncology, and more. For more information, please visit www.abcellera.com .
AbCellera Forward-looking Statements
This document contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this document other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, plans, objectives for future operations, and the evaluation of our available liquidity to execute on our strategy (including our ability to access our reimbursement based R&D government contributions). The use of certain data derived from cross-study comparisons are not based on any head-to-head clinical trials. Cross-study comparisons are inherently limited and may suggest misleading similarities and differences and are presented for informational purposes. In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.
These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties, other factors, and definition of our business metrics are described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this document represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.
Inquiries Media: Tiffany Chiu; media@abcellera.com , +1(236)521-6774 Partnering: Murray McCutcheon, Ph.D.; partnering@abcellera.com , +1(604)559-9005 Investor Relations: Peter Ahn; ir@abcellera.com , +1(778)729-9116

Frequently Asked Questions

When will AbCellera present at investor conferences?

AbCellera will present on November 11 and 16, 2026.

Where can I access the live webcast of the presentations?

The webcast will be available on AbCellera's Investor Relations website.

What is AbCellera's focus area?

AbCellera focuses on developing antibody-based medicines.

What are the names of the conferences AbCellera will attend?

The conferences are the Stifel Healthcare Conference and Jefferies Global Healthcare Conference.

Last updated: Oct 22, 2026